Iovance Biotherapeutics is trading 4.04% down at $10.21 as U.S. equities weaken. - The Nasdaq is down 1.03%, with investors reacting to firmer yields, renewed oil-driven inflation concerns and cautious risk sentiment. - No clear company-specific negative announcement was identified for September 23, 2026. - Recent company coverage remains positive, including record Amtagvi revenue, but predates today’s decline.